Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
NVCT - Nuvectis Pharma, Inc.
Market Cap 236.75M P/E - EPS this Y 27.30% Ern Qtrly Grth -
Income -21.1M Forward P/E -11.74 EPS next Y - 50D Avg Chg -9.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 27.00%
Dividend N/A Price/Book 19.13 EPS next 5Y - 52W High Chg -21.00%
Recommedations 1.70 Quick Ratio 3.14 Shares Outstanding 18.65M 52W Low Chg 138.00%
Insider Own 53.26% ROA -60.89% Shares Float 6.64M Beta 0.46
Inst Own 11.42% ROE -128.44% Shares Shorted/Prior 0.98M/0.90M Price 14.79
Gross Margin - Profit Margin - Avg. Volume 67,432 Target Price 22.00
Oper. Margin - Earnings Date Aug 6 Volume 44,798 Change 7.41%
Healthcare | Biotechnology | United States
About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Nuvectis Pharma, Inc. News
12/10/24 Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
11/25/24 Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
11/15/24 Nuvectis Pharma reports data from Phase 1b study of NXP800
11/14/24 Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
11/14/24 Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
11/13/24 Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why
11/07/24 Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
11/05/24 Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
10/28/24 PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
10/23/24 Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
10/07/24 Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
09/24/24 Here's Why We're Watching Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
09/16/24 PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
09/05/24 Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/30/24 Nuvectis’ NXP800 gains FDA ODD for cancer treatment
08/29/24 Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
08/28/24 Positive Signs As Multiple Insiders Buy Nuvectis Pharma Stock
08/06/24 Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
07/28/24 Insiders hold 65% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recently
05/28/24 7 Penny Biotech Stocks to Triple Your Investment
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BENTSUR RON Chairman & CEO Chairman & CEO Oct 06 Buy 11.23 1,080 12,128 3,236,844 10/10/23
BENTSUR RON Chairman & CEO Chairman & CEO Oct 04 Buy 11.02 3,220 35,484 3,235,764 10/06/23
BENTSUR RON Chairman & CEO Chairman & CEO Aug 15 Buy 14.75 350 5,162 3,232,544 08/16/23
BENTSUR RON Chairman & CEO Chairman & CEO Aug 08 Buy 14.75 300 4,425 3,232,194 08/11/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 31 Buy 13.88 860 11,937 2,595,000 08/01/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 28 Buy 13.91 2,584 35,943 2,594,140 07/31/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 27 Buy 13.98 1,556 21,753 2,591,556 07/28/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 26 Buy 13.97 10,000 139,700 2,590,000 07/27/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 19 Buy 14.84 8,000 118,720 2,571,762 07/20/23
BENTSUR RON Chairman & CEO Chairman & CEO Jul 19 Buy 14.33 200 2,866 3,231,559 07/20/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 18 Buy 14.84 9,149 135,771 2,563,762 07/19/23
BENTSUR RON Chairman & CEO Chairman & CEO Jul 07 Buy 15.61 260 4,059 3,231,359 07/18/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 12 Buy 15.09 3,285 49,571 2,554,613 07/13/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 11 Buy 15.36 10,000 153,600 2,551,328 07/12/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 07 Buy 15.19 8,948 135,920 2,541,328 07/10/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 06 Buy 15.01 3,179 47,717 2,532,380 07/07/23
BENTSUR RON Chairman & CEO Chairman & CEO Jul 06 Buy 14.88 320 4,762 3,231,099 07/07/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 05 Buy 15.52 1,176 18,252 2,529,201 07/06/23
Mosseri Marlio Charles 10% Owner 10% Owner Jun 26 Buy 16.46 16,760 275,870 2,528,025 06/27/23
BENTSUR RON Chairman & CEO Chairman & CEO Jun 26 Buy 16.50 750 12,375 3,230,779 06/27/23
Mosseri Marlio Charles 10% Owner 10% Owner Jun 23 Buy 17.43 73,175 1,275,440 2,511,265 06/26/23
Mosseri Marlio Charles 10% Owner 10% Owner Jun 21 Buy 17.72 13,090 231,955 2,438,090 06/23/23
Mosseri Marlio Charles 10% Owner 10% Owner Jun 16 Buy 17.75 12,700 225,425 2,425,000 06/20/23
Mosseri Marlio Charles 10% Owner 10% Owner Jun 15 Buy 17.63 32,124 566,346 2,412,300 06/16/23
BENTSUR RON Chairman & CEO Chairman & CEO Jun 07 Buy 17.47 350 6,114 3,229,529 06/08/23
BENTSUR RON Chairman & CEO Chairman & CEO May 31 Buy 17.28 330 5,702 3,229,179 06/01/23
BENTSUR RON Chairman & CEO Chairman & CEO May 16 Buy 17.025 320 5,448 3,228,649 05/18/23
BENTSUR RON Chairman & CEO Chairman & CEO Mar 23 Buy 12.13 230 2,790 3,228,329 03/27/23
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer Mar 21 Buy 11.99 420 5,036 1,361,955 03/22/23
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer Mar 15 Buy 10.71 670 7,176 1,361,535 03/17/23
BENTSUR RON Chairman & CEO Chairman & CEO Nov 30 Buy 7.45 150 1,118 3,015,459 11/30/22
BENTSUR RON Chairman & CEO Chairman & CEO Nov 25 Buy 7.41 450 3,334 3,015,309 11/29/22
BENTSUR RON Chairman & CEO Chairman & CEO Nov 17 Buy 7.24 750 5,430 3,014,859 11/21/22
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer Nov 16 Buy 7.15 300 2,145 1,245,365 11/18/22
BENTSUR RON Chairman & CEO Chairman & CEO Sep 28 Buy 7.35 1,000 7,350 3,013,109 10/03/22
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer Sep 23 Buy 7.87 220 1,731 1,245,065 09/27/22
BENTSUR RON Chairman & CEO Chairman & CEO Sep 23 Buy 7.81 1,500 11,715 3,012,109 09/27/22
BENTSUR RON Chairman & CEO Chairman & CEO Sep 01 Buy 8.24 1,700 14,008 3,010,609 09/06/22
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer Sep 02 Buy 8.31 404 3,357 1,244,845 09/06/22
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer Aug 31 Buy 8.07 3,006 24,258 1,244,441 09/02/22
BENTSUR RON Chairman & CEO Chairman & CEO Aug 23 Buy 9.04 1,500 13,560 3,008,909 08/30/22
BENTSUR RON Chairman & CEO Chairman & CEO Aug 18 Buy 8.79 19,426 170,755 3,007,409 08/22/22
BENTSUR RON Chairman & CEO Chairman & CEO Jun 28 Buy 11.72 4,000 46,880 2,968,314 06/30/22
BENTSUR RON Chairman & CEO Chairman & CEO Jun 22 Buy 12.23 700 8,561 2,964,314 06/27/22
BENTSUR RON Chairman & CEO Chairman & CEO May 26 Buy 15.82 1,000 15,820 2,963,614 05/31/22
BENTSUR RON Chairman & CEO Chairman & CEO May 19 Buy 17.62 1,200 21,144 2,962,614 05/23/22
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer May 20 Buy 16.54 300 4,962 1,241,435 05/23/22
BENTSUR RON Chairman & CEO Chairman & CEO May 17 Buy 19.92 2,010 40,039 2,961,414 05/19/22
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer May 16 Buy 19.42 242 4,700 1,241,135 05/18/22
BENTSUR RON Chairman & CEO Chairman & CEO May 13 Buy 18.71 1,700 31,807 2,959,404 05/17/22